Standard Biotools (LAB) Free Cash Flow (2010 - 2026)

Standard Biotools (LAB) has 17 years of Free Cash Flow data on file, last reported at -$46.9 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 32.77% year-over-year to -$46.9 million in Q1 2026; TTM through Mar 2026 was -$86.8 million, a 26.05% increase from a year earlier, with the FY2025 full-year figure at -$75.2 million, up 48.24% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$46.9 million, down from -$1.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for LAB reached as high as -$1.9 million in Q4 2025 and fell as low as -$63.3 million in Q1 2024.
• Historically, Free Cash Flow has averaged -$23.8 million across 5 years, with a median of -$19.9 million in 2022.
• Across the five-year window, Free Cash Flow sank 3887.2% in 2022 and soared 82.51% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$19.9 million in 2022, then soared by 43.28% to -$11.3 million in 2023, then rose by 3.61% to -$10.9 million in 2024, then surged by 82.51% to -$1.9 million in 2025, then slumped by 2361.49% to -$46.9 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$46.9 million in Q1 2026, -$1.9 million in Q4 2025, and -$22.2 million in Q3 2025.